VEZAAR PLUS TABLETS

Losartan Potassium 50 mg + Hydrochlorothiazide 12.5 mg

Oral tablets | Pack size: 2 x 10 tablets

COMPOSITION

Each tablet contains **Losartan Potassium 50 mg** and **Hydrochlorothiazide 12.5 mg**. Excipients: according to the approved Vezaar Plus formulation.

THERAPEUTIC CLASS

Antihypertensive combination: angiotensin II receptor blocker (ARB) and thiazide diuretic. Primary medical segment: Cardiology; also Internal Medicine.

PHARMACOLOGY

Losartan blocks the angiotensin II AT1 receptor, reducing vasoconstriction and aldosterone effects. Hydrochlorothiazide increases renal excretion of sodium and chloride, contributing to reduced blood pressure. Their complementary actions provide additive antihypertensive activity.

INDICATIONS

Treatment of hypertension in patients for whom combination therapy is appropriate. Certain approved labels also include reduction of stroke risk in patients with hypertension and left ventricular hypertrophy; confirm this indication in locally approved labeling.

DOSAGE AND ADMINISTRATION

Adults: The usual starting dose for the 50 mg/12.5 mg combination is **one tablet once daily**. If blood pressure remains inadequately controlled, a prescriber may adjust treatment after approximately 3 weeks; the usual maximum combination dose is losartan 100 mg/hydrochlorothiazide 25 mg daily. Do not increase dosage without medical advice.

METHOD OF ADMINISTRATION

Take orally with or without food, preferably at the same time each day. Swallow with water. Monitor blood pressure regularly. If a dose is missed, take it when remembered unless nearly time for the next dose; do not double doses.

BOXED WARNING: FETAL TOXICITY

Discontinue as soon as pregnancy is detected. Medicines acting on the renin-angiotensin system may cause fetal injury or death. Patients who are pregnant or planning pregnancy should promptly consult their prescriber for an alternative.

CONTRAINDICATIONS

Hypersensitivity to losartan, hydrochlorothiazide or other formulation components; anuria; and coadministration with aliskiren in patients with diabetes. Additional local contraindications may apply.

WARNINGS AND PRECAUTIONS

Correct volume or salt depletion before starting treatment to reduce symptomatic hypotension. Monitor renal function, serum potassium, sodium and other electrolytes. Kidney injury and changes in potassium may occur. Hydrochlorothiazide can cause hyponatraemia, hypokalaemia, hyperuricaemia and altered glucose tolerance.

EYE AND SKIN PRECAUTIONS

Hydrochlorothiazide may rarely cause acute myopia and secondary angle-closure glaucoma; sudden eye pain or reduced vision requires urgent care. Photosensitivity and non-melanoma skin cancer risk have been associated with hydrochlorothiazide exposure; advise sun protection and skin monitoring.

SPECIAL POPULATIONS

Avoid use or reassess carefully in severe renal impairment; hydrochlorothiazide may be less effective at low kidney function. The fixed combination is not recommended as initial therapy in hepatic impairment under some labels. Older adults may be more susceptible to hypotension and electrolyte disturbances.

DRUG INTERACTIONS

Potassium supplements, potassium-sparing diuretics and potassium-containing salt substitutes may increase potassium. NSAIDs may impair kidney function and reduce antihypertensive effects. Lithium toxicity risk may increase. Other renin-angiotensin system blockers may increase renal and potassium risks. Antidiabetic drug adjustments may be needed.

PREGNANCY AND LACTATION

Do not use during pregnancy. Stop treatment promptly when pregnancy is recognized and seek medical advice. Hydrochlorothiazide is present in breast milk; breastfeeding during combination treatment requires an individualized clinical decision.

ADVERSE REACTIONS

Dizziness, low blood pressure, fatigue, upper respiratory symptoms and back pain may occur. Serious effects include renal dysfunction, severe electrolyte disturbances, allergic reactions and acute angle-closure glaucoma. Seek immediate care for facial swelling, fainting or sudden visual changes.

OVERDOSAGE

Overdose may cause marked hypotension, tachycardia or bradycardia, dehydration and electrolyte imbalance. Seek emergency medical attention. Management is supportive, with monitoring of fluid status, kidney function and electrolytes.

STORAGE

Store in the original packaging according to Vezaar Plus approved storage conditions; protect from moisture. Keep out of reach of children. Do not use after expiry.

PRESENTATION

Vezaar Plus Tablets 50 mg/12.5 mg: pack of **2 x 10 tablets**.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.